Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
About this study
A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms of cell survival. This will facilitate targeting and termination of these survival/ resistance pathways before they develop with rational combinations of therapeutic agents to improve outcomes.
- Condition
- Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROSE Cluster 1, BRAF V600E
- Sponsor
- University of Colorado, Denver
Who can join
- Age
- 18 to 85 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 20
- Minimum age: 18 years
- Maximum age: 85 years
- Study condition: Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROSE Cluster 1, BRAF V600E
- Targetable Oncogene - Biopsy Cohort (includes blood draw)
- Carry a diagnosis of locally advanced or stage IV NSCLC responsive to targeted therapies (per current NCCN guidelines)
- Aged 18 years or older
- ECOG 0-2
- Have a histologically confirmed diagnosis of NSCLC harboring an activating mutation responsive to targeted therapy (per NCCN guidelines)
- No prior systemic therapy for locally advanced or metastatic disease.
- Planned treatment with targeted therapy specific to the oncogene driver mutation.
- Patients must have at least one site of measurable disease ≥ 2cm.
- Primary disease site or site of metastatic disease must be amenable to biopsy.
- Patients must have the ability to understand and willingness to sign an informed consent document.
- Targetable Oncogene - Blood Draw Only Cohort
- Carry a diagnosis of locally advanced or stage IV NSCLC responsive to targeted therapy (per NCCN guidelines)
- No prior systemic therapy or radiotherapy for metastatic lung cancer (surgery alone permitted)
- Declines repeat biopsy option or does not have tumor site amenable to biopsy.
- Immunotherapy Cohort - Blood Draw Only
- Have a histologically confirmed diagnosis of locally advanced or stage IV NSCLC without a treatable activating mutation that would be amenable to targeted therapy AND planned first line treatment with immunotherapy or chemotherapy plus immunotherapy.
- No prior systemic therapy or radiation therapy for lung cancer (surgery alone permitted)
Exclusion 7
- Targetable Oncogene - Biopsy Cohort (includes blood draw)
- Concurrent health problem which would preclude tissue biopsy (e.g. hemophilia or other bleeding predisposition).
- Patients whose only biopsy source would involve sampling an anatomic area that carries an unacceptably high procedural risk (e.g. pericardium or kidney) as deemed by the treating physician or by a proceduralist performing the biopsy.
- Patients whose only biopsy source involves a sample that may not be evaluable due to insufficient genomic material (such as cerebrospinal or ascitic fluid) as deemed by the treating physician. .
- Targetable Oncogene Cohort and Immunotherapy Cohort - Blood Draw Only
- Planned follow up on therapy outside of the University of Colorado Health System
- Unwillingness to allow for residual clinical biopsy specimens to be utilized in this study.
Where
1 site, 1 recruiting
University of Colorado, Cancer Center
Aurora, Colorado, United States
Contact
-
Brandi Kubala
303-724-1657 brandi.kubala@cuanschutz.edu
Potential match only. Final eligibility is determined by the study team.